Clinical trials: Cancer Breast
Breast Cancer
Cryoablation of Low Risk Small Breast Cancer- ICE3 Trial
To evaluate the efficacy of cryoablation without lumpectomy and its impact on local and distant recurrence of early stage breast cancer .
- Trial name
- NCT02200705
- Testing
- Ice-Sense3TM/ ProSenseTM
- Where
- 19 sites in United States
- Volunteers
- 206 people
- Sponsor
- IceCure Medical Ltd.
Breast Cancer, Neutropenia
Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
This is a randomized, double-blind and placebo controlled phase 3 study to evaluate the efficacy and safety of F-627 in women with stage II-IV breast cancer receiving chemotherapy treatment.
- Trial name
- NCT02872103
- Testing
- F-627
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- EVIVE Biotechnology
Breast Cancer
Supine MRI in Breast Cancer Patients Undergoing Upfront Surgery or Receiving Neoadjuvant Therapy
This research study involves the use of a common breast imaging modality (magnetic resonance imaging, 'MRI') and is investigating its role in evaluating surgical decision making for breast cancer when it is performed with the…
- Trial name
- NCT02956473
- Testing
- Supine MRI, Neoadjuvant Therapy (NAT), Ultrasound
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- Dana-Farber Cancer Institute
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments
Comparison of olaparib vs. physician's choice of single agent standard of care non-platinum based chemotherapy in patients with germline Breast Cancer susceptibility gene (gBRCA) mutated ovarian cancer who have progressed at…
- Trial name
- SOLO3 (NCT02282020)
- Testing
- OLAPARIB, Single agent chemotherapy
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 266 people
- Sponsor
- AstraZeneca
HER2+ Metastatic Breast Cancer (MBC)
A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
This is a randomized, multi-center, multinational, open-label, active-controlled, parallel design study of the combination of neratinib plus capecitabine versus the combination of lapatinib plus capecitabine in HER2+ MBC patients…
- Trial name
- NALA (NCT01808573)
- Testing
- neratinib, capecitabine, lapatinib
- Where
- 252 sites in United States, Argentina and 26 more
- Volunteers
- 621 people
- Sponsor
- Puma Biotechnology, Inc.
Breast Cancer
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
A randomized multi-arm study evaluating the efficacy and safety of nivolumab versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in participants with high-risk…
- Trial name
- CheckMate 7FL (NCT04109066)
- Testing
- nivolumab, paclitaxel (PTX), anthracycline
- Where
- 240 sites in United States, Argentina and 30 more
- Volunteers
- 521 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Breast Cancer, Thyroid Dysfunction
Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma
Up to one third of breast cancer patients have hypothyroidism or hyperthyroidism. L-thyroxine (T4), or Synthroid, is the most commonly prescribed agent for the management of hypothyroidism in the US.
- Trial name
- B-TREUH (NCT03787303)
- Testing
- Triiodothyronine (T3)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Aultman Health Foundation
Metastatic Breast Cancer
A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)
This is a multicenter, Phase II, randomized, controlled, open label trial designed to provide a preliminary assessment of the safety and efficacy of sunitinib when combined with bevacizumab and paclitaxel in patients who have not…
- Trial name
- NCT00434356
- Testing
- bevacizumab, sunitinib, paclitaxel
- Volunteers
- 46 people
- Sponsor
- Genentech, Inc.
Breast Adenocarcinoma, Deleterious BRCA1 Gene Mutation
Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer
This phase II trial studies the side effects of talazoparib when given before standard therapy in treating patients with breast cancer that has spread to nearby healthy tissue and has a mutation in a breast cancer, early onset…
- Conditions
- Breast Adenocarcinoma, Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, HER2/Neu Negative
- Trial name
- NCT02282345
- Testing
- Laboratory Biomarker Analysis, Talazoparib
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Breast Cancer
Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy
A retrospective observational analysis of de-identified Flatiron Health Analytic Database to describe patient characteristics, treatment patterns and effectiveness of Palbociclib + AI as first-line therapy in HR+/HER2- metastatic…
- Trial name
- NCT04176354
- Testing
- Palbociclib + an aromatase inhibitor, Palbociclib + Letrozole, Letrozole
- Where
- United States
- Volunteers
- 813 people
- Sponsor
- Pfizer
Breast Cancer
HylaCare in the Treatment of Acute Skin Changes in Patients Undergoing Radiotherapy for Breast Cancer
This will be a randomized, double blind, vehicle-controlled evaluation of the effectiveness and safety of HylaCareTM. The study will employ the patient as her own control, a commonly used method for the evaluation of topical…
- Trial name
- NCT02165605
- Testing
- HylaCare
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Texas Southwestern Medical Center
Triple Negative Breast Cancer
LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer
This study evaluates efficacy of LY3023414 and prexasertib in patients with metastatic triple negative breast cancer.
- Trial name
- NCT04032080
- Testing
- Drug 1: LY3023414; Drug 2: Prexasertib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Baylor Research Institute
Healthy Volunteers, Breast Cancer
Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer Patients
Primary purpose of the clinical study is to evaluate the safety, biodistribution and radiation dosimetry of [131I]-SGMIB Anti-HER2 VHH1 in healthy volunteers and patients with HER2+ breast cancer.
- Trial name
- CAM-VHH1 (NCT02683083)
- Testing
- [131I]-SGMIB Anti-HER2 VHH1
- Where
- Belgium
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Precirix
Bone Loss, Osteoporosis
Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy
Elderly, postmenopausal women with breast cancer on aromatase inhibitors are at increased risk of developing bone loss and osteoporosis.
- Conditions
- Bone Loss, Osteoporosis, Breast Cancer
- Trial name
- REBBeCA II (NCT00485953)
- Testing
- risedronate
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Susan L. Greenspan
Breast Cancer, Early Detection of Cancer
A Prospective Study to Evaluate Clinical Performance of Thermalytix in Detecting Breast Cancers
The purpose of this study is to determine the clinical performance of AI-based Thermalytix with the current standard-of-care diagnostic modalities in women.
- Trial name
- NCT04688086
- Testing
- Thermalytix
- Where
- India
- Volunteers
- 687 people, healthy volunteers welcome
- Sponsor
- Niramai Health Analytix Private Limited
Breast Cancer
Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving erlotinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be…
- Trial name
- NCT00633750
- Testing
- erlotinib hydrochloride, TUNEL assay, protein expression analysis
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Neutropenia, Breast Cancer
SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)
The purpose of this study was to compare the efficacy of a single dose of SPI-2012 versus pegfilgrastim in participants with early-stage breast cancer receiving docetaxel and cyclophosphamide (TC), as measured by the duration of…
- Trial name
- ADVANCE (NCT02643420)
- Testing
- SPI-2012, Pegfilgrastim, Docetaxel
- Where
- 81 sites in United States, Canada and 1 more
- Volunteers
- 406 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Post-Operative Nausea and Vomiting, Breast Cancer
Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)
The goal of this clinical research study is to learn if light electrical stimulation to the wrist area during surgery is feasible in women having breast surgery.
- Trial name
- NCT02473042
- Testing
- Electrical Stimulation, Zofran, Dexamethasone
- Where
- United States
- Volunteers
- 188 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Biopsy Wound
Pain Monitoring After Breast Biopsy: Benefit of E-health
Each year, approximately 1500 breast biopsies (1000 microbiopsies and 500 macrobiopsies) are performed in the radiologic department of the Montpellier Cancer Institute (ICM).
- Trial name
- BIO-PSY (NCT04456920)
- Testing
- phone consultation, e-PRO self-completed via connected objects (tablet/phone), visit
- Where
- France
- Volunteers
- 193 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
This phase I/II trial studies the best dose and effect of pimasertib in combination with bintrafusp alfa in treating patients with cancer that has spread to the brain (brain metastases).
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm, Hormone Receptor Positive Breast Adenocarcinoma
- Trial name
- NCT04789668
- Testing
- Bintrafusp Alfa, Pimasertib, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.